Patients

MOTPOLY XR offers steady 24-hour delivery with fewer fluctuations

Once-daily MOTPOLY XR is bioequivalent to twice-daily lacosamide¹

Lacosamide vs MOTPOLY XR mean concentration

Chart

MOTPOLY XR is bioequivalent at steady state (SS) blood levels for maximum serum concentration (C_max), minimum serum concentration (C_min), steady-state concentration (C_ss), and area under the curve (AUC).

With its bioequivalence at steady-state blood levels, MOTPOLY XR delivers 24-hour SustainAbility

Built-in time-release technology of
MOTPOLY XR delivers steady blood levels¹

Proven XR beaded capsule achieves once‑daily dosing¹

immediate release time

First layer of lacosamide releases immediately upon capsule breakdown

extended release time

XR coating controls the release rate of remaining lacosamide, resulting in steady, sustained release over time

capsule

Drug Layers:

Immediate Release
Extended Release

XR Coating

Bead Core

Consider once-daily MOTPOLY XR for adult patients who may benefit from once-daily dosing

Important issues in the treatment of epilepsy, particularly for seniors and younger adults

66^%

of adults with epilepsy have at least 4 other chronic conditions²

Among the most common are CNS- and psych-related disorders^3*†

~50^%

of patients with epilepsy take at least 5 multiple medications, 3x higher than the general population (15%)^4,5

In Medicare, it is 90% for people with epilepsy⁴

Younger adults with a busier lifestyle, including work and childcare⁶

*	Psychosocial concerns, depression, severe headache, anxiety, migraine, learning difficulties, intellectual and developmental disabilities, and autism spectrum disorders.^3,7
^†	Other non-CNS comorbidities include heart disease, stroke, hypertension, prediabetes, cancer, dermatitis, arthritis, emphysema, asthma, and ulcer.⁷
	CNS=central nervous system.

INDICATION

MOTPOLY XR is indicated for the treatment of partial-onset seizures in adults and in pediatric patients weighing at least 50 kg.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Antiepileptic drugs increase the risk of suicidal behavior and ideation. Monitor patients for the emergence or worsening of depression, suicidal thoughts or behaviors.

INDICATION

MOTPOLY XR is indicated for the treatment of partial-onset seizures in adults and in pediatric patients weighing at least 50 kg.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Antiepileptic drugs increase the risk of suicidal behavior and ideation. Monitor patients for the emergence or worsening of depression, suicidal thoughts or behaviors.
MOTPOLY XR may cause dizziness and ataxia in patients. Advise patients not to operate machinery or motor vehicles until they know how MOTPOLY XR affects them.
Obtain ECG before beginning MOTPOLY XR, and after titration to steady-state maintenance dose in patients with underlying proarrhythmic conditions or those on concomitant medications that affect cardiac conduction. Closely monitor these patients.
MOTPOLY XR may cause syncope in patients.
Gradually withdraw MOTPOLY XR to minimize the potential of increased seizure frequency.
Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)/multi-organ hypersensitivity has been reported and can be life-threatening or fatal. If signs or symptoms are present, immediately evaluate the patient. Discontinue MOTPOLY XR if there is no alternative etiology.

MOST COMMON ADVERSE REACTIONS

The most common adverse reactions in adults (≥10% and greater than placebo) are diplopia, headache, dizziness, nausea, and somnolence.

PREGNANCY: Based on animal data, MOTPOLY XR may cause fetal harm.

DRUG INTERACTIONS: Consider dose reduction in patients with renal or hepatic impairment taking strong inhibitors of CYP3A4 and CYP2C9.

Please refer to the full Prescribing Information and Medication Guide for MOTPOLY XR for additional important information.

References:
1. Data on file, Aucta Pharmaceuticals; 2022. 2. Centers for Disease Control. National Center for Chronic Disease Prevention and Health Promotion (NCCDPHP). Epilepsy. https://www.cdc.gov/chronicdisease/resources/publications/ factsheets/epilepsy.htm. Accessed July 12, 2023. 3. Scheffer IE, Berkovic B, Capovilla G. et al. ILAE classification of the epilepsies: position paper of the ILAE Commission for Classification and Terminology. Epilepsia. 2017;58(4):512-521. 4. Terman SW, Aubert CE, Maust DT, et al. Polypharmacy composition and patient- and provider-related variation in patients with epilepsy. Epilepsy Behav. 2022;126(4):108428. 5. Kantor ED, Rehm CD, Haas JS, Chan AT, Giovannucci EL. Trends in prescription drug use among adults in the United States from 1999-2012. JAMA. 2015;314(17):1818-1831. 6. Mendorf S, Prell T, Schönenberg A. Detecting reasons for nonadherence to medications in adults with epilepsy: a review of self-report measures and key predictors. J Clin Med. 2022;11(15):4308. 7. Centers for Disease Control. Comorbidity in adults with epilepsy—United States, 2010. MMWR. 2013;63(43);849-865.